FibroGen appoints Thane Wettig as permanent CEO and Board member, effective Oct 2, 2023

KYNTRA BIO, INC.

Thane Wettig promoted from Interim CEO to CEO and Board member as of Oct 2, 2023.
Mr. Wettig had served as Interim CEO since July 23, 2023.
Appointed as Class I director with term expiring at 2024 annual meeting.
Compensation terms remain per prior 8-K filed July 25, 2023.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Thane Wettig

Chief Executive Officer

KYNB · KYNTRA BIO, INC.

Effective: 2023-10-02
Filed: October 6, 2023, 7:59 PM ET

On October 2, 2023, the Board of Directors (the “Board”) of FibroGen, Inc. (the “Company”) appointed Interim Chief Executive Officer Thane Wettig as (i) Chief Executive Officer and (ii) a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Thane Wettig was appointed as Chief Executive Officer at KYNTRA BIO, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On October 2, 2023, the Board of Directors (the “Board”) of FibroGen, Inc. (the “Company”) appointed Interim Chief Executive Officer Thane Wettig as (i) Chief Executive Officer and (ii) a member of the Board.

View on SEC.gov

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-052242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.